MME ISABELLE HONORE

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence

Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes

Auteur de référence en rhumatologie

36 articles scientifiques publiés — un praticien à la pointe de la recherche

Délais de RDV courts dans la région

336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS CEDEX 14 (75)HospitalierRPPS 10001587368

📊 Reconnaissance scientifique : 20/100📝 78 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 21/05/2026

MME ISABELLE HONORE est une rhumatologue hospitalière à Paris, avec une production scientifique significative (h-index de 20 et 78 publications). Ses recherches portent principalement sur l'épidémiologie, la pharmacovigilance et l'utilisation de l'intelligence artificielle en rhumatologie. Elle s'intéresse également à la qualité de vie des patients et à l'analyse de données en vie réelle.

Expertises présumées

Épidémiologie en rhumatologie
Pharmacovigilance en rhumatologie
Intelligence artificielle en rhumatologie
Qualité de vie des patients rhumatoïdes
Analyse de données en vie réelle (RWE)
Registres de maladies rhumatoïdes
Recherche en santé basée sur les données de vie réelle

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole

Antimicrobial agents and chemotherapy · 2012

📚 144 citations🎯 RCR 5.65Top 6% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ABSTRACT Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects. We hypothesized that A. fumigatus isolates in the sputum of CF subjects with previous exposure to itraconazole was associated with higher prevalence of azole resistance. From June 2010 to April 2011, sputum samples from adult CF subjects at Cochin University Hospital (France) were examined systematically for the detection of A. fumigatus . MICs of A. fumigatus isolates against azoles were screened using Etest, and reduced susceptibility to azoles was confirmed using the CLSI broth microdilution method. A. fumigatus was isolated from the sputum of 131/249 (52.6%) adult CF subjects, and 47/131 (35.9%) subjects had received previous treatment with itraconazole. Reduced A. fumigatus susceptibility to itraconazole (MIC, ≥2 mg/liter) was confirmed in 6/131 (4.6%) subjects. All 6 isolates also had reduced susceptibility to posaconazole (MIC, ≥0.5 mg/liter), and 3/6 isolates had reduced susceptibility to voriconazole (MIC, ≥2 mg/liter). Mutations in the cyp51A gene were detected at positions previously implicated to cause resistance in 5 isolates. Azole-resistant A. fumigatus isolates were found in 5/25 (20%) subjects exposed to itraconazole within the previous 3 years. High rates of azole-resistant A. fumigatus isolates were present in adult CF subjects and were associated with recent itraconazole exposure. Although the clinical implications of these findings will require further studies, the cautious use of itraconazole in adult CF subjects can be recommended.

Infertility in an adult cohort with primary ciliary dyskinesia: phenotype-gene association

The European respiratory journal · 2017

📚 103 citations🎯 RCR 4.81Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant

The European respiratory journal · 2023

📚 88 citations🎯 RCR 13.24Top 2% NIH

Lire l'abstract Crossref ↓

BackgroundThe European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) for people with cystic fibrosis (pwCF) carrying at least one F508del variant. The United States Food and Drug Administration (FDA) also approved ETI for pwCF carrying one of 177 rare variants.MethodsAn observational study was conducted to evaluate the effectiveness of ETI in pwCF with advanced lung disease that were not eligible to ETI in Europe. All patients with no F508del variant and advanced lung disease (defined as having a percent predicted forced expiratory volume (ppFEV1)<40 and/or being under evaluation for lung transplantation) and enrolled in the French Compassionate Program initiated ETI at recommended doses. Effectiveness was evaluated by a centralized adjudication committee at 4–6 weeks in terms of clinical manifestations, sweat chloride concentration and ppFEV1.ResultsAmong the first 84 pwCF included in the program, ETI was effective in 45 (54%) and 39 (46%) were considered to be non-responders. Among the responders 22/45 (49%) carried aCFTRvariant that is not currently approved by FDA for ETI eligibility. Important clinical benefits, including suspending the indication for lung transplantation, a significant decrease in sweat chloride concentration by a median [IQR] −30 [-14;-43]mmol·l−1(n=42;p<0.0001) and an improvement in ppFEV1by+10.0 [6.0; 20.5] (n=44,p<0.0001), were observed in those for whom treatment was effective.ConclusionClinical benefits were observed in a large subset of pwCF with advanced lung disease andCFTRvariants not currently approved for ETI.

Cookies & analyse de trafic

MME ISABELLE HONORE

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (36) — classées par pathologie

Transversal28

Épidémiologie & registres2

Vraie vie / RWE2

IA en rhumatologie1

Pharmacovigilance1

Qualité de vie / PROMs1

Revue générale1

Partager cette fiche